Literature DB >> 20686792

A new classification for hepatocellular carcinoma with portal vein tumor thrombus.

Jie Shi1, Eric C H Lai, Nan Li, Wei-Xing Guo, Jie Xue, Wan-Yee Lau, Meng-Chao Wu, Shu-Qun Cheng.   

Abstract

BACKGROUND/
PURPOSE: We aimed to correlate the survival of patients with hepatocellular carcinoma (HCC) with macroscopic portal vein tumor thrombus (PVTT) who underwent partial hepatectomy with or without portal thrombectomy with our PVTT classification. Currently, different staging systems for HCC are widely used in clinical practice. However, they lack the refinement in giving prognosis and guiding surgical treatment once macroscopic PVTT is present.
METHODS: A retrospective study was carried out, in a single tertiary center, from January 2001 to December 2004 on 441 patients who underwent partial hepatectomy with or without portal thrombectomy for HCC with macroscopic PVTT. Overall survival was examined to determine whether it was correlated with our PVTT classification, and with the TNM staging, Cancer of the Liver Italian Program (CLIP) scoring system, and the Japan Integrated Staging (JIS) scoring system.
RESULTS: With our PVTT classification, the numbers (percentages) of patients with types I, II, III, and IV PVTT were 144 (32.7%), 189 (42.9%), 86 (19.5%), and 22 (5.0%), respectively. The corresponding 1-, 2-, and 3-year overall survival rates for types I to IV PVTT were 54.8, 33.9, and 26.7%; 36.4, 24.9, and 16.9%; 25.9, 12.9, and 3.7%; and 11.1, 0, and 0%, respectively (log-rank of the survival curves P < 0.0001). Using the TNM system, the majority of patients were classified as stage III (n = 379 or 85.9%). Similarly, the majority of patients (n = 388 or 88.0%) were classified as having CLIP scores of 2 (n = 143, or 32.4%), 3 (n = 171, or 38.8%), and 4 (n = 74, or 16.8%). The 1-, 2-, and 3-year overall survivals for these 3 CLIP scores were very similar. Using the JIS score, the majority of patients (n = 372 or 84.4%) were classified with a JIS score of 2. The 1-, 2-, and 3-year overall survivals of patients with a JIS score of 2 were worse than those of the patients with a JIS score of 1 (this was expected) as well as being worse than those with a JIS score of 3 (this was unexpected). Thus, the latter 3 systems of classification were not refined enough, and they were inadequate for stratifying HCC with macroscopic PVTT treated with partial hepatectomy with or without thrombectomy.
CONCLUSIONS: In patients with HCC with macroscopic PVTT treated by partial hepatectomy with or without thrombectomy, our PVTT classification better stratified and predicted prognosis than the TNM staging, CLIP scoring system, and JIS scoring system, which were unrefined and inadequate for this group of patients.

Entities:  

Mesh:

Year:  2011        PMID: 20686792     DOI: 10.1007/s00534-010-0314-0

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  59 in total

1.  Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification.

Authors:  Zhi-Jie Niu; Yi-Long Ma; Ping Kang; Sheng-Qiu Ou; Zhi-Bin Meng; Zhi-Kun Li; Feng Qi; Chang Zhao
Journal:  Med Oncol       Date:  2011-12-27       Impact factor: 3.064

Review 2.  Staging systems for hepatocellular carcinoma: Current status and future perspectives.

Authors:  Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Kazuhiko Koike; Hirokazu Nishino; Hisao Tajiri
Journal:  World J Hepatol       Date:  2015-03-27

3.  Hepatocellular carcinoma with main portal vein tumor thrombus: a comparative study comparing hepatectomy with or without neoadjuvant radiotherapy.

Authors:  Nan Li; Shuang Feng; Jie Xue; Xu-Biao Wei; Jie Shi; Wei-Xing Guo; Wan-Yee Lau; Meng-Chao Wu; Shu-Qun Cheng; Yan Meng
Journal:  HPB (Oxford)       Date:  2016-05-07       Impact factor: 3.647

Review 4.  Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016.

Authors:  Stephen L Chan; Charing C N Chong; Anthony W H Chan; Darren M C Poon; Kenneth S H Chok
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

5.  Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma.

Authors:  Saleh A Alqahtani; Faisal M Sanai; Ashwaq Alolayan; Faisal Abaalkhail; Hamad Alsuhaibani; Mazen Hassanain; Waleed Alhazzani; Abdullah Alsuhaibani; Abdullah Algarni; Alejandro Forner; Richard S Finn; Waleed K Al-Hamoudi
Journal:  Saudi J Gastroenterol       Date:  2020-10       Impact factor: 2.485

6.  Clinical Trigonometry: Right Hepatic Trisegmentectomy After Radiation Trisegmentectomy for Hepatocellular Carcinoma.

Authors:  Ashley L Titan; Kelly Devereaux; John D Louie; George A Poultsides
Journal:  Dig Dis Sci       Date:  2017-11-08       Impact factor: 3.199

7.  Outcomes of anatomical versus non-anatomical resection for hepatocellular carcinoma according to circulating tumour-cell status.

Authors:  Lu-Nan Qi; Liang Ma; Yuan-Yuan Chen; Zu-Shun Chen; Jian-Hong Zhong; Wen-Feng Gong; Yan Lu; Bang-De Xiang; Le-Qun Li
Journal:  Ann Med       Date:  2020-01-20       Impact factor: 4.709

8.  The role of three-dimensional imaging in optimizing diagnosis, classification and surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus.

Authors:  Xu-Biao Wei; Jie Xu; Nan Li; Ying Yu; Jie Shi; Wei-Xing Guo; Hong-Yan Cheng; Meng-Chao Wu; Wan-Yee Lau; Shu-Qun Cheng
Journal:  HPB (Oxford)       Date:  2015-11-17       Impact factor: 3.647

9.  Portal vein tumor thrombus in advanced hepatocellular carcinoma: A case report.

Authors:  Xianli Chen; Liguan Liu; Xingnan Pan
Journal:  Oncol Lett       Date:  2015-04-14       Impact factor: 2.967

10.  Clinical significance of microRNA-155 expression in hepatocellular carcinoma.

Authors:  Chengnong Guan; Feng Yang; Xichun He; Tuhua Li; Qingmei Yang; Huiping He; Meng Xu
Journal:  Oncol Lett       Date:  2015-12-22       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.